title: Dose response of prophylactic antipsychotics.
abstract: A review of the literature concerning the use of oral and depot antipsychotic medication has high-lighted some important considerations in the treatment of chronic schizophrenic patients. All patients not treated with any form of antipsychotic drug will relapse within 3 years. These relapses will be more clinically significant and will occur at greater frequency than in patients who receive medication on a regular basis. Careful consideration should be given to each patient when choosing between oral or depot medication and inpatient or outpatient therapy. In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance. One option for the prevention of relapse without an increase in adverse side effects is the administration of depot haloperidol. For all therapeutic options, medication should be given on a regular basis, since intermittent dosing strategies do not work, and psychosocial rehabilitation should be initiated.
authors.affiliation: Illinois State Psychiatric Institute, Chicago.
authors.forename: J M
authors.initials: JM
authors.lastname: Davis
authors.forename: J M
authors.initials: JM
authors.lastname: Kane
authors.forename: S R
authors.initials: SR
authors.lastname: Marder
authors.forename: B
authors.initials: B
authors.lastname: Brauzer
authors.forename: B
authors.initials: B
authors.lastname: Gierl
authors.forename: N
authors.initials: N
authors.lastname: Schooler
authors.forename: D E
authors.initials: DE
authors.lastname: Casey
authors.forename: M
authors.initials: M
authors.lastname: Hassan
mesh_terms: D000284:Administration, Oral; D000359:Aftercare; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005476:Fluphenazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D010349:Patient Compliance; D011613:Psychotherapy; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy* / Q000517:prevention & control / Q000534:rehabilitation; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; C033563:haloperidol decanoate; C011825:fluphenazine depot; D006220:Haloperidol; D005476:Fluphenazine